光生物调节：一种新兴的抑郁症治疗方式。
Photobiomodulation: An Emerging Treatment Modality for Depression.
机构信息
Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital (MGH), 149 13th Street (2612), Boston, MA 02129, USA; Department of Psychiatry, Harvard Medical School (HMS), 25 Shattuck Street, Boston, MA 02115, USA; Department of Anatomy, Institute of Biomedical Sciences (ICB), University of Sao Paulo (USP), 2415 Prof. Lineu Prestes Avenue, Sao Paulo, SP 05508-000, Brazil.
Clinical Research Division, Nathan Kline Institute (NKI) for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University (NYU) School of Medicine, 550 First Avenue, New York, NY 10016, USA.
出版信息
Psychiatr Clin North Am. 2023 Jun;46(2):331-348. doi: 10.1016/j.psc.2023.02.013. Epub 2023 Mar 25.
Major depressive disorder (MDD) is considered a global crisis. Conventional treatments for MDD consist of pharmacotherapy and psychotherapy, although a significant number of patients with depression respond poorly to conventional treatments and are diagnosed with treatment-resistant depression (TRD). Transcranial photobiomodulation (t-PBM) therapy uses near-infrared light, delivered transcranially, to modulate the brain cortex. The aim of this review was to revisit the antidepressant effects of t-PBM, with a special emphasis on individuals with TRD. A search on PubMed and ClinicalTrials.gov tracked clinical studies using t-PBM for the treatment of patients diagnosed with MDD and TRD.
重度抑郁症（MDD）被认为是一场全球危机。MDD 的常规治疗包括药物治疗和心理治疗，但相当数量的抑郁症患者对常规治疗反应不佳，被诊断为治疗抵抗性抑郁症（TRD）。经颅光生物调节（t-PBM）疗法使用近红外光经颅传递来调节大脑皮层。本综述的目的是重新评估 t-PBM 的抗抑郁作用，特别关注 TRD 患者。在 PubMed 和 ClinicalTrials.gov 上进行了检索，以追踪使用 t-PBM 治疗被诊断为 MDD 和 TRD 的患者的临床研究。
Zotero 插件